chlorthalidone has been researched along with Kidney Diseases in 18 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared with either treatment alone." | 7.80 | Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome. ( Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ, 2014) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| "Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared with either treatment alone." | 3.80 | Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome. ( Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, C | 1 |
| Jeon, Y | 1 |
| Kleven, DT | 1 |
| Pollock, JS | 1 |
| White, JJ | 1 |
| Pollock, DM | 1 |
| Nakagawa, T | 1 |
| Johnson, RJ | 1 |
| Rahman, M | 2 |
| Ford, CE | 1 |
| Cutler, JA | 1 |
| Davis, BR | 2 |
| Piller, LB | 1 |
| Whelton, PK | 2 |
| Wright, JT | 2 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 1 |
| Haywood, LJ | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Oparil, S | 1 |
| Preston, R | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| KOCAK, N | 1 |
| TELAFERLI, A | 1 |
| THAYER, JM | 1 |
| HEALY, FA | 1 |
| DUNLOP, D | 1 |
| BAGROS, P | 1 |
| JENNINGS, RC | 1 |
| SHAIKH, VA | 1 |
| ALLEN, WM | 1 |
| OECHSLIN, RJ | 1 |
| SCHMID, JR | 1 |
| RAO, CR | 1 |
| Pressel, S | 1 |
| Nwachuku, C | 1 |
| Barzilay, J | 1 |
| Batuman, V | 1 |
| Eckfeldt, JH | 1 |
| Farber, MA | 1 |
| Franklin, S | 1 |
| Henriquez, M | 1 |
| Kopyt, N | 1 |
| Louis, GT | 1 |
| Saklayen, M | 1 |
| Stanford, C | 1 |
| Walworth, C | 1 |
| Ward, H | 1 |
| Wiegmann, T | 1 |
| Bufalari, A | 1 |
| Meloni, G | 1 |
| Schiffl, H | 1 |
| Weidmann, P | 1 |
| Meier, A | 1 |
| Ziegler, WH | 1 |
| Imhof, PR | 1 |
| Hushak, J | 1 |
| Schumann, G | 1 |
| Dukor, P | 1 |
| Wagner, J | 1 |
| Keller, HM | 1 |
| Gastaldi, L | 1 |
| Buccianti, G | 1 |
| Rizzato, G | 1 |
| Marazzini, L | 1 |
| Urakabe, S | 1 |
| Orita, Y | 1 |
| Furukawa, T | 1 |
| Abe, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
2 reviews available for chlorthalidone and Kidney Diseases
| Article | Year |
|---|---|
MANAGEMENT OF RENAL DYSFUNCTION IN CONGESTIVE HEART FAILURE.
Topics: Acetazolamide; Benzothiadiazines; Chlorthalidone; Diuretics; Heart Failure; Humans; Kidney Diseases; | 1963 |
[MECHANISM OF ACTION AND CLINICAL USE OF DIURETICS].
Topics: Bendroflumethiazide; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Diuretics; Hydrochlorothiazi | 1963 |
3 trials available for chlorthalidone and Kidney Diseases
| Article | Year |
|---|---|
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Excretion of urinary casts after the administration of diuretics.
Topics: Chemical Precipitation; Chlorthalidone; Clinical Trials as Topic; Diuresis; Diuretics; Ethacrynic Ac | 1972 |
13 other studies available for chlorthalidone and Kidney Diseases
| Article | Year |
|---|---|
Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Arterial Pressure; Atrasentan; Cell A | 2014 |
Hypertension: Is there a dark side to thiazide therapy for hypertension?
Topics: Chlorthalidone; Chronic Disease; Disease Progression; Diuretics; Humans; Hypertension; Kidney Diseas | 2010 |
Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Female; Glomerular Filtration Rate; Humans; Hyp | 2012 |
[On the effects and methods of clinical use of chlorthalidone].
Topics: Chlorthalidone; Diuretics; Heart Diseases; Humans; Hypertension; Kidney Diseases; Liver Cirrhosis | 1962 |
[THE TREATMENT OF EDEMA WITH SULFONAMIDE DIURETICS].
Topics: Acetazolamide; Acidosis; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Dehydration; Diuretics; | 1964 |
RENAL ISCHAEMIA DUE TO THROMBOSIS OF RENAL ARTERY RESULTING FROM METASTASES FROM PRIMARY CARCINOMA OF THE BRONCHUS.
Topics: Adrenal Gland Neoplasms; Angiography; Bronchi; Bronchial Neoplasms; Chlorthalidone; Diagnosis, Diffe | 1964 |
[EXTREMELY SEVERE HYPOELECTROLYTEMIA DUE TO SALIDIURETIC ADDICTION].
Topics: Alkalosis; Chlorthalidone; Diet, Sodium-Restricted; Electrocardiography; Hypokalemia; Kidney Disease | 1964 |
CLINICAL AND BIOCHEMICAL STUDIES ON A NEW DIURETIC: CHLORTHALIDONE.
Topics: Adolescent; Chlorthalidone; Diuretics; Drug Therapy; Edema; Geriatrics; Heart Failure; Kidney Diseas | 1964 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
[The behavior of uricemia during treatment with spironolactone and with other diuretics].
Topics: Acetazolamide; Adolescent; Adult; Aged; Chlorthalidone; Clopamide; Diuretics; Ethacrynic Acid; Femal | 1967 |
Relationship between plasma catecholamines and urinary catecholamine excretion rates in normal subjects and certain diseased states.
Topics: Adult; Blood Pressure; Chlorthalidone; Creatinine; Diabetes Mellitus; Electrolytes; Epinephrine; Fem | 1981 |
[Some aspects of renal metabolism of citric acid].
Topics: Adult; Age Factors; Aged; Chlorthalidone; Citrates; Heart Failure; Humans; Hydrochlorothiazide; Hype | 1970 |
Analysis of urea excretion with special reference to the influence of abrupt change in urine flow.
Topics: Adult; Animals; Chlorides; Chlorthalidone; Diabetes Insipidus; Diuresis; Female; Humans; Hydrochloro | 1965 |